<DOC>
	<DOC>NCT00240552</DOC>
	<brief_summary>This open-label study will enable HIV-infected adults with limited treatment options to receive fosamprenavir until commercial supplies are available in Switzerland.</brief_summary>
	<brief_title>Fosamprenavir Expanded Access</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Fosamprenavir</mesh_term>
	<criteria>HIV1 infected subjects. Subjects must belong to one of the following populations: 1. Subjects with limited treatment options due to viral resistance, interactions, or tolerability issues with other antiretroviral drugs. 2. Subjects who already receive amprenavir (AgeneraseÂ®) 3. Subjects for whom once daily dosing of antiretroviral therapy is indicated, including, once daily dosing with fosamprenavir/ritonavir.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>protease inhibitor</keyword>
	<keyword>Treatment Experienced</keyword>
	<keyword>amprenavir</keyword>
	<keyword>fosamprenavir</keyword>
	<keyword>GW433908</keyword>
	<keyword>HIV</keyword>
	<keyword>pro drug</keyword>
</DOC>